Ruben Niesvizky, M.D., professor of medicine, Weill Cornell Medicine, spoke to OncLive about sequencing agents for patients with multiple myeloma.
Sequential therapy is part of the natural algorithms for the disease, Niesvizky explains. In the future, he says, he can foresee achieving minimal residual disease (MRD) negativity and hopefully offer patients disease-free and drug-free states. That will only be possible, however, once patients are randomized to receive treatment or not, depending on the MRD state, in clinical trials.
Moreover, researchers need to better define MRD, he adds. Imaging will be important and will be incorporated into that question.